Chen Peng, Piaggi Paolo, Traurig Michael, Bogardus Clifton, Knowler William C, Baier Leslie J, Hanson Robert L
Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1550 E. Indian School Rd, Phoenix, AZ, 85014, USA.
Diabetologia. 2017 Apr;60(4):645-655. doi: 10.1007/s00125-016-4203-1. Epub 2017 Jan 26.
AIMS/HYPOTHESIS: Individuals exposed to maternal diabetes in utero are more likely to develop metabolic and cardiovascular diseases later in life. This may be partially attributable to epigenetic regulation of gene expression. We performed an epigenome-wide association study to examine whether differential DNA methylation, a major source of epigenetic regulation, can be observed in offspring of mothers with type 2 diabetes during the pregnancy (OMD) compared with offspring of mothers with no diabetes during the pregnancy (OMND).
DNA methylation was measured in peripheral blood using the Illumina HumanMethylation450K BeadChip. A total of 423,311 CpG sites were analysed in 388 Pima Indian individuals, mean age at examination was 13.0 years, 187 of whom were OMD and 201 were OMND. Differences in methylation between OMD and OMND were assessed.
Forty-eight differentially methylated CpG sites (with an empirical false discovery rate ≤0.05), mapping to 29 genes and ten intergenic regions, were identified. The gene with the strongest evidence was LHX3, in which six CpG sites were hypermethylated in OMD compared with OMND (p ≤ 1.1 × 10). Similarly, a CpG near PRDM16 was hypermethylated in OMD (1.1% higher, p = 5.6 × 10), where hypermethylation also predicted future diabetes risk (HR 2.12 per SD methylation increase, p = 9.7 × 10). Hypermethylation near AK3 and hypomethylation at PCDHGA4 and STC1 were associated with exposure to diabetes in utero (AK3: 2.5% higher, p = 7.8 × 10; PCDHGA4: 2.8% lower, p = 3.0 × 10; STC1: 2.9% lower, p = 1.6 × 10) and decreased insulin secretory function among offspring with normal glucose tolerance (AK3: 0.088 SD lower per SD of methylation increase, p = 0.02; PCDHGA4: 0.08 lower SD per SD of methylation decrease, p = 0.03; STC1: 0.072 SD lower per SD of methylation decrease, p = 0.05). Seventeen CpG sites were also associated with BMI (p ≤ 0.05). Pathway analysis of the genes with at least one differentially methylated CpG (p < 0.005) showed enrichment for three relevant biological pathways.
CONCLUSIONS/INTERPRETATION: Intrauterine exposure to diabetes can affect methylation at multiple genomic sites. Methylation status at some of these sites can impair insulin secretion, increase body weight and increase risk of type 2 diabetes.
目的/假设:子宫内暴露于母体糖尿病的个体在生命后期更易患代谢和心血管疾病。这可能部分归因于基因表达的表观遗传调控。我们进行了一项全表观基因组关联研究,以检查与孕期无糖尿病母亲的后代(OMND)相比,孕期患有2型糖尿病母亲的后代(OMD)中是否能观察到作为表观遗传调控主要来源的DNA甲基化差异。
使用Illumina HumanMethylation450K BeadChip检测外周血中的DNA甲基化。对388名皮马印第安人个体的总共423,311个CpG位点进行了分析,检查时的平均年龄为13.0岁,其中187人为OMD,201人为OMND。评估了OMD和OMND之间的甲基化差异。
鉴定出48个差异甲基化的CpG位点(经验性错误发现率≤0.05),这些位点映射到29个基因和10个基因间区域。证据最充分的基因是LHX3,与OMND相比,OMD中有6个CpG位点发生高甲基化(p≤1.1×10)。同样,PRDM16附近的一个CpG在OMD中发生高甲基化(高1.1%,p = 5.6×10),其中高甲基化也预测了未来患糖尿病的风险(甲基化每增加1个标准差,风险比为2.12,p = 9.7×10)。AK3附近的高甲基化以及PCDHGA4和STC1处的低甲基化与子宫内暴露于糖尿病有关(AK3:高2.5%,p = 7.8×10;PCDHGA4:低2.8%,p = 3.0×10;STC1:低2.9%,p = 1.6×10)并且与葡萄糖耐量正常的后代胰岛素分泌功能降低有关(AK3:甲基化每增加1个标准差降低0.088个标准差,p = 0.02;PCDHGA4:甲基化每降低1个标准差降低0.08个标准差,p = 0.03;STC1:甲基化每降低1个标准差降低0.072个标准差,p = 0.05)。17个CpG位点也与体重指数有关(p≤0.05)。对至少有一个差异甲基化CpG的基因进行的通路分析(p<0.005)显示,有三个相关生物学通路富集。
结论/解读:子宫内暴露于糖尿病可影响多个基因组位点的甲基化。这些位点中某些位点的甲基化状态可损害胰岛素分泌、增加体重并增加患2型糖尿病的风险。